Evotec SE (EVO) Research

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.

Market snapshot

Symbol
EVO
Price
$2.56
Day change
-1.92%
Market cap
$822.3M
P/E ratio
-4.24x
52-week range
2.31-4.42
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months
Analyst price target
$7.00

Recent news

  • Evotec vows to further engage with investor MAK, who demanded change

    Evotec said on Tuesday it would continue a dialogue with investor MAK Capital, ​which has published a list of ‌changes it wants the German biotech firm to make.

Peer companies

  • Alvotech (ALVO)
  • Azenta, Inc. (AZTA)
  • Harrow Health, Inc. (HROW)
  • NovoCure Limited (NVCR)
  • Pacira BioSciences, Inc. (PCRX)
  • Pharvaris N.V. (PHVS)
  • Schrödinger, Inc. (SDGR)
  • Spyre Therapeutics, Inc. (SYRE)

Recent insider activity

  • Anderson Mark Monroe — A-Award (100000 shares) on 2018-10-22
  • Anderson Mark Monroe — trade (0 shares) on 2018-10-22
  • Smith Scott Clifford — A-Award (100000 shares) on 2018-08-13
  • Smith Scott Clifford — trade (0 shares) on 2018-08-13
  • LAFFER ARTHUR B — A-Award (100000 shares) on 2018-08-13

Open Evotec SE (EVO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.